FDMT · 4D Molecular Therapeutics, Inc. · Financials
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $92.01M | $85.21M | $37K | $20.72M | $3.13M | $18.04M | $13.61M | $6.99M | |
| $240.31M | $195.7M | $141.3M | $97.1M | $80.25M | $61.36M | $53.04M | $38.72M | |
| $48.82M | $49.06M | $46.58M | $36.49M | $32.91M | $28.01M | $17.24M | $13.9M | |
| $5.03M | $4.69M | $4.65M | $4.2M | $2.4M | $1.52M | $1.44M | $1M | |
| $289.12M | $244.76M | $187.88M | $133.59M | $113.16M | $89.37M | $70.28M | $57.75M | |
| -$197.12M | -$159.55M | -$187.84M | -$112.87M | -$110.03M | -$71.33M | -$56.66M | -$50.76M | |
| — | -187.24% | -507678.38% | -544.65% | -3516.52% | -395.46% | -416.28% | -726.65% | |
| -$192.09M | -$154.85M | -$183.19M | -$108.66M | -$107.63M | -$69.81M | -$55.22M | -$49.76M | |
| $18.15M | $19.48M | $27.05M | $12.21M | $2.57M | $137K | $152K | $1.5M | |
| $17.94M | $19.44M | $26.97M | $12.03M | $2.54M | $16K | -$29K | $1.46M | |
| $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | |
| -$179.18M | -$140.11M | -$160.87M | -$100.84M | -$107.49M | -$71.32M | -$56.69M | -$49.31M | |
| — | -164.43% | -434778.38% | -486.59% | -3435.41% | -395.37% | -416.49% | -705.78% | |
| -$179.96M | -$139.61M | -$160.66M | -$99.63M | -$108.27M | -$71.74M | -$56.69M | — | |
| USD/shares | -$2.63 | -$2.42 | -$2.98 | -$2.58 | -$3.32 | -$2.57 | — | — |
| USD/shares | -$2.63 | -$2.42 | -$2.98 | -$2.58 | -$3.32 | -$2.57 | — | — |
| shares | — | 57.93M | 53.94M | 39.13M | 32.35M | 27.73M | 6.43M | 5.14M |
| shares | — | 57.93M | 53.94M | 39.13M | 32.35M | 27.73M | 6.43M | 5.14M |
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 286 similar-size Biotechnology companies (of 516 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Japan | $85,000,000 | $0 | — | — | — | — | — |
| United States | $209,000 | $37,000 | $20,156,000 | $35,000 | $121,000 | -$27,000 | $666,000 |
| Australia | — | — | — | — | — | — | $7,000 |
| Switzerland | — | — | — | — | $17,181,000 | $12,897,000 | $6,287,000 |
| Netherlands | — | — | $567,000 | $3,094,000 | $736,000 | $742,000 | $26,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Collaboration and License Revenue | $85,209,000 | $37,000 | $20,723,000 | $3,129,000 | $18,038,000 | $13,612,000 | $6,986,000 |